Neovacs Financial Statements From 2010 to 2024
| ALNEV Stock | EUR 0.0002 0.00 0.00% |
Check Neovacs SA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neovacs SA's main balance sheet or income statement drivers, such as , as well as many indicators such as . Neovacs financial statements analysis is a perfect complement when working with Neovacs SA Valuation or Volatility modules.
Neovacs |
Neovacs SA Company Shares Outstanding Analysis
Neovacs SA's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Neovacs SA Shares Outstanding | 590.99 M |
Most of Neovacs SA's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neovacs SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Neovacs SA has 590.99 M of shares currently outstending. This is 227.36% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The shares outstanding for all France stocks is 3.35% lower than that of the firm.
Neovacs SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neovacs SA's current stock value. Our valuation model uses many indicators to compare Neovacs SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neovacs SA competition to find correlations between indicators driving Neovacs SA's intrinsic value. More Info.Neovacs SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neovacs SA's earnings, one of the primary drivers of an investment's value.About Neovacs SA Financial Statements
Neovacs SA shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Neovacs SA investors may analyze each financial statement separately, they are all interrelated. The changes in Neovacs SA's assets and liabilities, for example, are also reflected in the revenues and expenses on on Neovacs SA's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. Neovacs S.A. was founded in 1993 and is based in Paris, France. NEOVACS operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 24 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Neovacs Stock Analysis
When running Neovacs SA's price analysis, check to measure Neovacs SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neovacs SA is operating at the current time. Most of Neovacs SA's value examination focuses on studying past and present price action to predict the probability of Neovacs SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neovacs SA's price. Additionally, you may evaluate how the addition of Neovacs SA to your portfolios can decrease your overall portfolio volatility.